Zhejiang East-Asia Pharmaceutical (605177.SH): The raw material drug Lu Likang received the South Korean raw material drug registration certificate.
East Asia Pharmaceutical (605177.SH) issued an announcement that they recently received approval from the South Korean Food and Drug Administration (Korea...
Zhejiang East-Asia Pharmaceutical (605177.SH) announced that recently, the company has received the raw material drug registration certificate from the South Korean Ministry of Food and Drug Safety (Korean MFDS) for the product named Voriconazole. Voriconazole is used to treat skin superficial fungal infections caused by sensitive fungi, such as athlete's foot, body ringworm, jock itch, and can also be used for cutaneous candidiasis and tinea versicolor.
The receipt of the Voriconazole raw material drug registration certificate in South Korea marks the company's eligibility for market access in South Korea. This will have a positive impact on expanding the company's presence in the South Korean pharmaceutical market, thus promoting the sales of Voriconazole raw material drugs in other overseas markets.
Related Articles

US Stock Market Move | Royal Caribbean Cruises (RCL.US) Falls 3% on Plan to Acquire Half of Sandals for $3 Billion

Meta (META.US) Wins More Wall Street Bullish Calls After Muse Goes Viral! Cantor Fitzgerald Raises Price Target to $860, Trillion-Dollar AI Agent Market in Sight

CENTRALCHINA MT (09982) plans to acquire a 25% stake in Lianheng Technology for HK$100 million, launching a "construction management + AI technology" business model.
US Stock Market Move | Royal Caribbean Cruises (RCL.US) Falls 3% on Plan to Acquire Half of Sandals for $3 Billion

Meta (META.US) Wins More Wall Street Bullish Calls After Muse Goes Viral! Cantor Fitzgerald Raises Price Target to $860, Trillion-Dollar AI Agent Market in Sight

CENTRALCHINA MT (09982) plans to acquire a 25% stake in Lianheng Technology for HK$100 million, launching a "construction management + AI technology" business model.






